Background. We estimated the effectiveness of inactivated influenza vaccines for the prevention of laboratoryconfirmed, medically attended influenza during 3 seasons with variable antigenic match between vaccine and patient strains.
Influenza is an important cause of death and serious illness in the United States. As a result, annual influenza vaccination is recommended for young children, elderly people, other individuals at high risk for serious influenza-related complications, and close contacts of these groups [1] . Antigenic drift necessitates frequent changes in the composition of influenza vaccines, and these changes must be specified 7-9 months in advance of the influenza season to allow for the production and distribution of vaccines [2] . Vaccine effectiveness (VE) in the field can vary from season to season, but several observational studies have suggested that influenza vaccine retains some effectiveness when antigenic drift has occurred between vaccine and circulating strains. However, it is difficult to generalize these results because influenza infection was not laboratory confirmed in most studies, nor was antigenic match determined for viruses recovered from study participants [3] [4] [5] [6] [7] [8] . We conducted population-based case-control studies to estimate the annual effectiveness of trivalent inactivated influenza vaccine for preventing medically attended, laboratoryconfirmed influenza illness during 3 consecutive influenza seasons. Influenza viruses recovered from study participants were characterized each season to assess antigenic match.
METHODS

Study population.
The source population included residents of the Marshfield Epidemiologic Study Area (MESA), a dynamic, population-based cohort of approximately 54,000 residents living in 14 zip code areas surrounding Marshfield, Wisconsin. In this area, nearly all residents receive their inpatient and outpatient care from Marshfield Clinic facilities, which use an electronic medical record that captures 90% of outpatient visits, 99% of deaths, and 95% of hospital discharges for the population [9 -12] . Prior to each influenza season, we identified MESA residents for whom influenza vaccination was recommended by the Advisory Committee on Immunization Practices (ACIP) on the basis of age or individual risk of influenza complications. These individuals were eligible to be enrolled and tested for influenza during or after a clinical encounter for acute respiratory illness during the influenza season. For the 2004 -2005 season, community-dwelling residents of MESA were eligible to be enrolled with acute respiratory illness if they were 6 -23 months old or 65 years old on 1 November 1 2004, or if they were 2-64 years old and had been diagnosed with a high-risk medical condition [13] . For the 2005-2006 influenza season, eligibility was expanded to include all adults 50 years old, on the basis of ACIP recommendations for that season [14] . For the 2006 -2007 season, eligibility was further expanded to include all children 6-59 months old, on the basis of the then-current ACIP recommendations [15] .
Each season, individuals were classified as having a medical condition that placed them at high risk for complications of influenza infection if they had 2 visits to the Marshfield Clinic during the preceding 12 months that involved an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code for a high-risk condition. The ICD-9 codes included diagnoses in the following chronic disease categories: cardiac disease, pulmonary disease, renal disease, liver disease, diabetes mellitus, immunosuppressive disorders, malignancies, neurological/musculoskeletal disease, metabolic disease, cerebrovascular disease, and circulatory system disease.
Influenza vaccination and immunization status. Marshfield Clinic providers and local vaccination clinics used only trivalent inactivated influenza vaccine (Sanofi-Pasteur) during each influenza season. Despite concerns about vaccine availability in fall of 2004, Marshfield Clinic received sufficient doses to meet demand during all 3 seasons. Influenza vaccination status was determined by a real-time, internet-based vaccination registry used by all public and private vaccination providers serving the population (http:// www.recin.org). A validation study of the registry demonstrated that it correctly identified 96% to 98% of all influenza vaccinations that were delivered to the study population (E.A.B., unpublished data).
Adults and children were classified as immunized beginning 14 days after receipt of influenza vaccination. Children Ͻ9 years old were classified as fully immunized only if they had received 2 doses of influenza vaccine. Children in this age group were classified as partially immunized if they had received only 1 of 2 recommended doses. The number of partially immunized children was insufficient to generate a separate VE estimate, and they were excluded from all analyses.
Ascertainment of influenza illness. Members of the study cohort were recruited by trained research coordinators during or after an inpatient or outpatient medical encounter for acute respiratory illness of Ͻ10 days duration. Potential participants whose illness duration was 10 days (at the time of the encounter) were excluded because they were unlikely to test positive for influenza [16, 17] . Research coordinators used an electronic appointment system to identify and recruit eligible patients in all primary care clinics and in urgent care on weekdays, evenings, and weekends. Appointments made within the previous 3 days were selectively identified, which reduced the need to evaluate patients who were seen for a previously diagnosed condition. Patients with acute respiratory or febrile illness were identified by reviewing comments in the electronic appointment system or by querying the clinical staff. Eligible patients were also recruited at an acute care hospital that is contiguous with Marshfield Clinic (St. Joseph's Hospital). Most ill patients who were not approached during a clinical encounter were identified on the following day by use of electronic diagnosis codes entered by attending physicians (ICD-9-CM codes 382.0, 382.4, 382.9, 460 -466, 480, 483-486, 487, 490, 780.6, and 786.2). These individuals were contacted by telephone, and a swab sample was obtained at home from those who were eligible and consented.
A nasopharyngeal swab sample (from adults and children 13 years old) or nasal swab sample (from children 6 months-12 years old) was obtained from all participants [18, 19] . Most swab samples were obtained by research coordinators immediately after the clinical encounter, but samples obtained by clinical staff were used when available to avoid duplicate swabs. Each participant (or parent) completed a short interview to assess illness symptoms and onset date. Patients with laboratory-confirmed influenza were contacted again 14 days after enrollment to ascertain hospital admissions related to that illness. Ill patients with a negative influenza test could be reen-rolled with a new respiratory illness after a 28-day exclusion period to allow time for recovery from the first illness episode.
The date that study enrollment was initiated and the duration of recruitment varied by season. Control groups. Two control groups were used: traditional control subjects and test-negative control subjects. Traditional control subjects were randomly sampled with replacement each week from individuals in the source population who did not have a clinical encounter for acute respiratory illness prior to that week. These individuals were contacted by telephone and screened for the occurrence of any acute respiratory illness during the enrollment period. Traditional control subjects were enrolled in a 2:1 ratio to case subjects, with matching by week of case identification and age group (6 -23 [20] .
Calculation of vaccine effectiveness. VE was defined as [100 ϫ (1 Ϫ adjusted odds ratio)], where the odds ratio is for influenza vaccination among laboratory-confirmed influenza case subjects compared with control subjects. The odds ratio provided a valid estimate of the incidence rate ratio in the source population for analyses that used data from traditional control subjects, because incidence density sampling was used [21] . Traditional control subjects were matched to influenza case subjects with illness occurring in the same week. Exchangeable strata were pooled for the analysis that used data from traditional control subjects; conditional logistic regression was performed with strata defined by combinations of age group and week of case enrollment [22, 23] . The analysis that used data from traditional control subjects adjusted for age (as a continuous variable), presence of any high-risk condition, and frequency of health care use (sum of physician, laboratory, and radiology encounters) during the 12 months before the study population was established. The last covariate was included because vaccinated individuals were observed to use health-care services more often than unvaccinated individuals.
Test-negative control subjects were identified longitudinally throughout each influenza season in the same manner as case subjects, and independently of vaccination status. As a result, the corresponding odds ratio served as a valid estimate of the incidence rate ratio among participants even when the outcome (influenza) was not rare [21, 24] . Logistic regression models that used data from test-negative control subjects were adjusted for week of enrollment, age, interval from symptom onset to sample collection, and presence of any high-risk medical condition. Exact logistic regression was performed for subgroup analyses when indicated.
All analyses were performed using SAS (version 9.1; SAS Institute); P Ͻ .05 was considered significant. This study was reviewed and approved by the Marshfield Clinic Institutional Review Board, and all participants or parents gave written informed consent for influenza testing.
RESULTS
The number of patients approached for enrollment ranged from (table 2) .
Less than 10% of potential traditional control subjects declined to participate each season, and 54%-68% were matched to an influenza case. Exclusion due to prior respiratory illness was the primary reason for not being matched to a case. The demographic and clinical characteristics of case patients with laboratory-confirmed influenza and test-negative control subjects are shown in table 3.
The VE estimate obtained by using data from test-negative control subjects was highest for (table 5) . VE was estimated separately in children and adults in analysis that used data from testnegative control subjects, and the 95% confidence intervals included 0 in all age groups that were examined. However, the VE point estimates were highest for the 2006 -2007 season (data not shown).
VE was estimated for the subgroup of case subjects and testnegative control subjects who were tested 0 -3 days after illness Ineligible because symptom duration 10 days 304 (27) 194 (27) 498 (27) 216 (34) 166 (35) 382 (35) 318 (27) 250 (23) 568 (25) Ineligible for other reason c 74 (7) 53 (7) 127 (7) 75 (12) 56 (12) 131 (12) 192 (16) 103 (10) 295 (13) Refused 227 (20) 173 (24) 400 (22) 124 (20) 104 (22) 228 (21) 202 (17) 255 (24) subjects who were hospitalized after outpatient enrollment) were vaccinated, compared with 56% of test-negative control subjects, yielding a VE estimate of 90% (95% CI, 10%-100%) by use of exact logistic regression. The estimated VE was similar when hospitalized influenza case subjects were compared with hospitalized, influenza-negative control subjects: 10 (67%) of 15 hospitalized, influenza-negative control subjects had re- Interval from symptom onset to swab sample collection 0-2 days 78 (48) 183 (31) 20 (41) 94 (32) 41 (41) 218 (28) 3-4 days 54 (33) 183 (31) 17 (35) 73 (25) 36 (36) 235 (30) 5-6 days 21 (13) 120 (20) 7 (14) 55 (19) 16 (16) 156 (20) 7-10 days 11 (7) 112 (19) 5 (10) 75 (25) 7 (7) 162 (21 NOTE. Data are proportion (%) or %. Participants were classified as immunized beginning 14 days after receipt of influenza vaccination. Partially immunized children who had received only 1 of 2 recommended doses were excluded from analyses. CI, confidence interval.
a Logistic regression models adjusted for age, week of enrollment, interval from symptom onset to collection of swab sample, and presence of any high-risk medical condition. ceived influenza vaccination, yielding an unadjusted VE of 88% (95% CI, 13%-100%) by use of exact logistic regression. Three of four hospitalized case subjects and 12 of 15 hospitalized control subjects were Ͼ50 years old.
The proportion of influenza viruses isolated from patients that were well matched to vaccine strains was 3 of 62 (5%) NOTE. Data are proportion (%) or %. Traditional control subjects were sampled weekly from the population and matched to case subjects by age group. Participants were classified as immunized beginning 14 days after receipt of influenza vaccination. Partially immunized children who had received only 1 of 2 recommended doses were excluded. CI, confidence interval.
a Conditional logistic regression was performed with strata defined by combinations of age group and week of case enrollment. The analysis that used data from traditional control subjects adjusted for age, presence of any high risk condition, and frequency of health care use.
b In 2004 -2005, the number of case subjects involved in this analysis was lower than the number involved in the analysis that used data from test-negative control subjects because culture confirmation was delayed for 9 case subjects, which prevented sampling of traditional control subjects from the same week. Table 6 . Antigenic characteristics of influenza viruses isolated from study patients. A/H3N2 viruses recovered from study participants were closely matched to the vaccine strains. were well matched to vaccine strains. We used data from 2 control groups to generate VE estimates. The traditional control subjects were randomly sampled each week, with age matching, from a defined population of individuals for whom influenza vaccination was recommended. Although control subjects of this type are commonly used for casecontrol studies, they may introduce a bias in a study of VE for medically attended influenza. The vaccinated individuals in our study population used health-care services more often than unvaccinated individuals, and they were more likely to seek care for acute respiratory illness during the influenza season. As a result, vaccinated individuals with influenza were enrolled and tested more often than unvaccinated individuals with influenza, resulting in underestimation of VE when traditional control subjects were used as the comparison group. This bias was avoided in the case-control analysis based on test-negative control subjects, who sought care during the same period as influenza case subjects.
DISCUSSION
Simulation models suggest that the use of test-negative control subjects for estimating VE yields a point estimate that is nearly identical to the "true" VE in a simulated population if the test specificity is nearly 100%, as is likely when RT-PCR is used for case detection [25] . However, the simulations did not evaluate the effects of bias or confounding on VE estimates. We found that VE was consistently higher in the analysis that used data from test-negative control subjects, and this control group was most similar to the case subjects in terms of health-care seeking behavior. These findings suggest that analysis of data from testnegative control subjects may yield more unbiased estimates of VE, compared with analyses based on traditional control subjects. Our results also suggest that differential health-care seeking behavior is a more important source of bias, compared with the potential misclassification of true case subjects as testnegative control subjects when using a diagnostic method that is Ͻ100% sensitive. Additional research is needed to assess the optimal comparison group in studies that use laboratoryconfirmed influenza as the outcome.
Several randomized, placebo-controlled studies demonstrated efficacy of 58%-88% for currently licensed trivalent inactivated influenza vaccines [26 -30] . One of these studies found that VE was high (86%) during a season when the vaccine and circulating viruses were well matched, and it was not significantly greater than 0 during another season with a poor match between vaccine antigens and circulating viruses [29] . A trial involving healthy adults aged 30 -60 years over 5 seasons (1983-1984 through 1987-1988) found that vaccinated individuals had a significantly reduced risk of developing laboratory-confirmed influenza A illness during the 2 seasons with the best antigenic match [31] . A more recent randomized clinical trial that involved healthy adults 18 -46 years old reported that inactivated influenza vaccine had 77% efficacy for preventing laboratoryconfirmed influenza illness during the 2004 -2005 season, despite circulation of a drifted A(H3N2) virus in the study population [32] . The trial was performed in a nearby state (Michigan), and efficacy was based on testing of all participants with acute respiratory illness, including illnesses that were managed at home. In contrast, we measured effectiveness against medically attended, laboratory-confirmed influenza. Our study population also included a high proportion of older adults and individuals with a high-risk medical condition, and these groups were not included in the Michigan trial. Impaired humoral and cell-mediated vaccine response may contribute to reduced clinical effectiveness in older adults [26, 33] , although a recent review concluded that persistence of vaccine-induced antibody is not reduced in elderly individuals [34] .
Observational studies have suggested that inactivated influenza vaccine retains some effectiveness during seasons with a poor antigenic match [3] [4] [5] [6] [7] [8] . However, most studies used nonspecific outcome measures (i.e., influenza infections were not confirmed), and they did not assess the antigenic characteristics of viruses recovered from study participants. VE was estimated for the prevention of laboratory-confirmed influenza in British Columbia during the 2005-2006 season, when there was substantial mismatch between vaccine strains and influenza viruses recovered from study participants [35] . Sentinel physicians enrolled patients with influenzalike illness (ILI) and influenza was detected by culture or RT-PCR in 47% of subjects; VE was 61% for laboratory-confirmed influenza. The British Columbia study used an analytic approach that was similar to ours, but there are differences that limit direct comparison of the VE estimates in Wisconsin and British Columbia. First, physicians in British Columbia tested only half the patients presenting with ILI, and the criteria for testing were not clear. The high proportion of positive influenza tests suggests they may have preferentially selected patients with typical influenza symptoms for testing. Second, the age distribution was different in the 2 populations, with a higher proportion of elderly individuals in Wisconsin. The proportion of participants with a high-risk condition was also higher in Wisconsin (54%), compared with British Columbia (14%). Because the British Columbia study enrolled a younger and healthier population, it is plausible that VE may have been higher in that study.
Our study has several limitations. First, the estimation of VE using test-negative control subjects is a new approach with little precedent. Test-negative control subjects are similar to case subjects in terms of health-care seeking behavior, but they likely differ from the source population in other ways that affect generalizability. Second, the outcome measure used in this study is not directly comparable to outcome measures used in previous studies. We assessed VE for the prevention of medically attended, laboratory-confirmed influenza, and it is not known how this outcome measure compares with VE for preventing all influenza illness. Third, our study had limited power to estimate VE for the prevention of hospitalization or death. A larger, multisite study would be required to estimate VE for those outcomes. Finally, the sensitivity and specificity of real-time RT-PCR for influenza virus detection have not been fully evaluated, although it is more sensitive than culture [36, 37] . Misclassification of case status may have contributed to underestimation of VE because of false-negative RT-PCR results. This is a particular concern for patients who were tested later in the course of illness, when viral shedding is reduced.
Assessments of VE against laboratory-confirmed influenza in populations for whom annual influenza vaccination is recommended may influence influenza control recommendations if results are available while the influenza season is underway. For example, increased use of influenza diagnostic tests and antiviral agents may be recommended if lower VE is demonstrated as a result of poor antigenic match, as was the case for influenza B during the first 3 weeks of the 2007-2008 season in Wisconsin [38] . In addition, the use of standard VE assessments during multiple seasons will help clarify the relationship between antigenic match and clinical VE. Similar assessments will be needed during the early stages of a pandemic vaccination program, when it is likely that pandemic or prepandemic vaccines will be administered after limited immunogenicity and safety trials have been completed.
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